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The structural and functional complexity of the hu­
man interferon system has become increasingly evident. 
More than eight different alpha (leukocyte) interferons 
are expressed in induced human cells in culture. Many 
of these have been purified by a combination of methods, 
including high-performance liquid chromatography. 
Moreover, at least 12 different human leukocyte inter­
ferons have been cloned, and several have been effi­
ciently expressed in Escherichia coli and other orga­
nisms. The availability of purified species of leukocyte 
interferon, both natural and recombinant, has allowed 
structural work to be done, including amino acid se­
quence determinations, chemical modification studies, 
and the crystallization of one species. The purified ma­
terial has also been used for the production of mono­
clonal antibodies with various specificities that are 
proving invaluable in rapid assays and purification 
techniques. Testing of the purified species for their rel­
ative potency in antiviral, antiproliferative, and immu­
nomodulatory assays has begun to demonstrate the func­
tional uniqueness and diversity of the purified alpha 
interferons. Hybrid interferon genes have been synthe­
sized by splicing together parts of various cloned inter­
feron genes. The resulting hybrid proteins have been 
valuable in establishing structure/function relation­
ships. In several cases, the functional properties of the 
hybrid protein were novel and unpredicted from the 
properties of the parental molecules. 
Interferon was discovered by Isaacs and Lindenmann during 
an investigation of the phenomenon of viral interference, 
wherein infection by one virus produces resistance to subse­
quent infection by other, apparently unrelated viruses. Their 
work [1,2] and that of others [3] demonstrated that cells could 
respond to challenge with a virus or with other substances 
(subsequently termed inducers) by producing a substance that 
could confer upon other cells resistance to subsequent viral 
attack. This substance, termed interferon, was characterized as 
a protein that had some species specificity, but that was fairly 
nonspecific in protecting against a wide range of viruses. 
Since that time, the complexity of the system has increased 
as more interferon species within an organism have been rec­
ognized and characterized and biological effects have been 
documented [4]. 
The chemical heterogeneity of the interferons has become 
increasingly evident (Table I). It was found that interferons 
produced by different cell types were either stable or labile at 
pH 2. This lead to the designation of types I and II, respectively. 
Further work demonstrated that there were two main antigen-
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ically distinguishable forms within the type I class. The type I 
and type II designations have now been superceded by a no· 
menclature based on antigenic properties and protein structure. 
Corresponding generalizations evolved that the different 
classes of interferons were produced by different cell types 
under the action of different inducers. These observations were 
the basis for the tripartite classification of leukocyte, fibroblast, 
and immune interferon. Because it is now recognized that some 
cells can simultaneously produce both leukocyte and fibroblast 
interferon, the classification based on producer-cell type has 
been considered inaccurate. Consequently, the human leuko· 
cyte, fibroblast, and immune interferons have been designated 
as a, /3, and I' classes, respectively. Subsequent work has 
demonstrated that there are at least 10 highly related human 
alpha interferons (IFN-a) each with characteristic chemical 
and biological properties and each encoded by a different gene. 
Thus far only a single protein species and gene have been 
isolated for the human /3 and I' interferons, although some 
evidence exists for heterogeneity of the /3 interferon [5] . There 
is some evidence that the a, /3, and I' classes do not encompass 
all the human interferons (reviewed in [5]). However, these 
other species have not yet been clearly defined. 
Work on the function of the interferons has demonstrated 
that they are capable of numerous effects in biological systems 
(Table II). Besides the antiviral effects, by which the interfer· 
ons were discovered and functionally defined, the interferons 
are also potent inhibitors of growth and exhibit a number of 
immunomodulatory effects. This combination of activities has 
stimulated tremendous interest in their physiological roles and 
in their potential therapeutic applications, especially against 
viruses and tumors. 
Considerable progress has been made in dissecting the bio­
chemistry of the antiviral response, particularly through the 
pathway involving the (2'-5')0Iigoadenylate synthetase (re­
viewed in [6]). The product ofthis enzyme modulates the action 
of several enzymes, including the activation of a latent endo­
ribonuclease, ribonuclease L, which can degrade viral RNA. 
Other antiviral effects, probably distinct from this pathway, 
have been demonstrated, and it is unlikely that all viruses are 
inhibited via the same biochemical pathway. Recent work has 
also shown that at least 12 proteins are induced in cells treated 
with IFN-a, with an additional 12 proteins induced with IFN­
I' [7]. Despite such recent progress, our knowledge of the 
biochemistry of the antiviral response is at an early stage. 
Moreover, it is likely that the antiproliferative and immuno· 
modulatory effects of interferon are mediated through currently 
unknown biochemical pathways. 
The ongoing expansion of biological and therapeutic work 
has been made possible by the availability of pure interferon. 
The purification and characterization of the leukocyte interfer­
ons from natural sources and the cloning and expression of 
these molecules in bacteria are allowing detailed investigations 
of the biological effects of the individual species and their 
interactions. This article summarizes recent advances in the 
purification and functional understanding of the human a 
(leukocyte) interferons and progress in defining the functional 
diversity of the individual molecular species. This article will 
emphasize the approaches and results obtained in our labora­
tory. 
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TABLE I. Classification and general properties of interferons 
Type 
Current nomen-
clature 
Usual source 
Stability at pH 2 
Number of spe-
cies 
Glycosylation 
Presence of in­
trons in genes 
(leukocyte) 
Buffy coat leukocytes 
+ 
>10 
{3 
(fibroblast) 
Fibroblasts 
+ 
l' 
+ 
II 
l' 
(immune) 
T -lymphocytes 
+ 
+ 
'Some evidence for additional !3 species has been presented. Genes for such 
species could contain introns [5]. 
b Possible that minor species may be glycosylated. 
TABLE II. Selected biological activities of interferons 
Antiviral 
Antigrowth 
Antitumor 
Immunomodulatory effects: 
NK cell enhancement 
T -ce II functions: 
Suppressor T cells 
Cytotoxic T cells 
Monocyte functions 
B-cell functions 
------
PURIFICATION AND PROPERTIES OF NATURAL 
LEUKOCYTE INTERFERONS 
Since the lack of pure interferon was a serious drawback to 
both basic and clinical studies, purification of the interferons 
was early recognized as a critical task. While a large number of 
classical and novel techniques were attempted, the low abun­
dance of the molecule and some of its physicochemical prop­
erties prevented its purification and characterization. 
Several developments allowed the successful purification of 
leukocyte interferon in our laboratory. These developments 
included a more rapid in vitro assay of antiviral activity, which 
took 16 hours rather than 3 days [8], an efficient inducible 
system for the production of interferon, and a new purification 
scheme. The purification scheme was made possible by the use 
of high-performance liquid chromatography (HPLC), which 
had been modified for the analysis of amino acids, peptides, 
and proteins at the picomole level by a sensitive fluorescence 
assay developed by Sidney Udenfriend, Stanley Stein, and their 
colleagues in our Institute [9J. 
The purification started with the induction of interferon in 
buffy coat leukocytes by Newcastle disease virus. Following 
several initial steps for the concentration and gross fractiona­
tion of the culture medium, the material was purified over a 
series of HPLC columns with results similar to those shown in 
Fig 1. Overall purification was about 60,000- to 80,000-fold 
from the initial incubation medium. These studies demonstra­
ted that human leukocyte interferon is actually a family of 
closely related proteins [10,11]. Purification of leukocyte inter­
ferons by other workers also demonstrated the existence of 
multiple species [12,13,13aJ. This purification, the first re­
ported for any leukocyte interferon, produced a sufficient quan­
tity to allow the first chemical analysis and the first amino acid 
analysis of any interferon. The major problem behind this 
success was that the starting material came from buffy coats 
taken from 50 to 100 blood donors per week for several months. 
With the demonstration that leukocytes from patients with 
chronic myelogenous leukemia (CML) were a rich source of 
interferon when induced, it was possible to use the same HPLC 
methodology for the purification of several species of leukocyte 
interferon from CML cells [14]. This purification permitted 
the amino acid analysis of several individual species [I1J. 
Moreover, it was then possible to look at the functional prop­
erties of the various natural species. The ability of the purified 
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natural interferons to protect either bovine MDBK cells or 
human fibroblasts from killing by viruses was compared (Table 
III). All purified species protected both bovine and human cells. 
However, while there is only a four-fold variation in the pro­
tection of the bovine cells by the various leukocyte interferons, 
greater variation was observed in human cells. Specifically, two 
of the leukocyte species, 1'3 and 1'5, were considerably less active 
on human cells than were the others. This demonstrated the 
functional heterogeneity within the leukocyte interferon family. 
These results also contributed to the growing realization that 
interferons are not species-specific, but rather have character-
g ..... 
0 
z 
« "-
0 "" 
"; 
c: 
� 
... 
u 
z ... 
u '" w "" 
0 
::J ..... ... 
... 
> 
;:: 
� ... "" 
I-T 1 l '  1 I !  1 T I l l  
60r--
I 
J 
80-
60t-
A 
60 70 
FRACTION NUMBER 
� 
.;;-
2 
x 
2-
z 
0 "" 
� "" ... I-
� 
FIG 1. High-performance liquid chromatography of interferon. Fol­
lowing concentration and initial purification, material was purified on 
LiChrosorb RP·8 at pH 7.5 (A). A small part of the column effluent 
was directed to the fluorescamine monitoring system for detection of 
protein; fractions were also tested for interferon antiviral activity. The 
pooled interferon peak of panel A was chromatographed on a Li­
Chrosorb Diol column at pH 7.5 (B). (The labels a, ti, and l' were for 
laboratory use, and all correspond to HPLC peaks; they do not repre­
sent leukocyte, fibroblast, and immune interferons, respectively). The 
abundant peak l' was separated into components by chromatography 
on LiChrosorb RP-8 at pH 4.0 (C). The most abundant peak in panel 
C was rechromatographed on LiChrosorb RP-8 (D). The major peak 
in panel D represents a single subtype of leukocyte (a) interferon. 
(Reproduced from [lO) with permission.) 
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istic patterns of activity on cells of different species. All these 
species exhibited antiproliferative activity [15]. 
Purification of multiple species was also accomplished with 
interferon produced by a continuous cell line, KG-I, which had 
been established from a patient with erythroleukemia [16]. 
Initial work in our laboratory demonstrated that KG-l was a 
good producer of interferon after proper growth and induction 
[17,18]. Eventually, eight major species of human interferon 
were purified from these cells [19]. These also showed wide 
differences in potency on human cells, whereas all were quite 
active on bovine cells. 
The purification of naturally induced human leukocyte in­
terferons conclusively established several concepts: (1) Multiple 
leukocyte interferon species can be induced simultaneously in 
cultured human cells. This immediately suggested the existence 
of multiple genes corresponding to each of these structurally 
distinct species. (2) These interferons are closely related, having 
similar, but not identical molecular weights, amino acid con­
tent, and tryptic maps. (3) Although all the species were active 
on both human and bovine cells, the relative specific activities, 
particularly on human cells, differed considerably. (4) No car­
bohydrate was detected on five of the purified species examined. 
This contradicted the previously accepted notion that all inter­
ferons were glycoproteins. 
In addition to demonstrating that the various human leuko­
cyte interferons differ in their ability to confer antiviral pro­
tection on human cells, it was desirable to test their efficacy in 
other functional assays. Evinger et al [15] compared the ability 
of the purified species to inhibit cell multiplication of the 
human lymphoblastoid Daudi cell line (Table IV). It was found 
that all the species exhibited antiproliferative activity on these 
cells, although their potencies differed. This supported the 
notion that the chemical differences of the leukocyte interferon 
TARLE III. S'pecific activities of human leukocyte interferons 
Species a 
'" 
(\''2 
#, 
#2 
i-io 
" 
,2 
,0 
,. 
1.5 
._-
Specific activity 
on bovine 
MDHK cells 
(unit·fmg)b -_ .. -_ . . 
2.6 X 10" 
4 X 108 
3.4 X 10" 
4 X lOB 
4 X 10" 
2.6 X 10" 
4 X lOB 
3.5 X 10· 
3.5 X 10" 
0.9 X lOB 
--' ._-- . _--_.--
Specific activity 
On human 
AG-17:l2 cells 
(unitsfmg)< . -- ._-
2.6 X 10" 
3 X 108 
4.4 X 10" 
2 X lOB 
3 X 10" 
2 X 108 
1.5 X 10" 
1.5 X 10' 
4 X 108 
2 X 10· 
Relative activity 
MDBK/AG-1732 
._----_._._--
1.0 
1.3 
0.8 
2.0 
1.3 
0.7 
2.7 
23.3 
0.9 
45.0 -- - .. __ ... . _-_ .. 
" The <i, !-i, , nomenclature is an internal laboratory notation denot­
ing peaks on HPLC columns. This nomenclature is unrelated to that 
of the three main classes of interferon. Data from [11]. 
b 25 percent. 
c 50 percent. 
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species are reflected in functional differences. In comparing the 
potency of each leukocyte interferon species in the antiproli­
ferative assay with its potency in the antiviral assay, it was 
found that the ratios of antiproliferative-to-antiviral activity 
differed dramatically. A similar conclusion was drawn from 
experiments on the ability of the leukocyte interferons to 
stimulate natural killer cells (Table IV). If the various effects 
of interferon-antiviral, antiproliferative, natural killer cell 
activation, etc.-were all mediated through the same biochem­
ical pathway, then it might be expected that the potency of a 
species in one assay would correlate with its potency in another 
assay. However, this was not observed. Thus the various effects 
must be mediated through different pathways. Where are the 
branchpoints in the pathways? How does a single interferon 
species generate different activities? These questions can be 
extended to the first molecular event-the binding of interferon 
to the cellular receptor. In the various assays on different 
human cell types, is the same cell surface receptor involved, or 
are there multiple receptors, each corresponding to a distinct 
biochemical pathway? Do different human cell types have 
different receptors, or is the same receptor able to trigger 
activities differentially following its activation? In summary, 
how is the cell able to respond uniquely to the various leukocyte 
interferons with resultant individual biochemical responses 
modulated to various degrees? 
EXPRESSION AND CHARACTERIZATION OF 
HUMAN INTERFERONS PRODUCED IN BACTERIA 
Although it was possible to purify sufficient quantities of 
interferons from induced cells in order to conduct the structural 
and functional studies described thus far, the purification from 
human cells was quite laborious. The techniques of recombi­
nant DNA technology presented the possibility of more easily 
producing large quantities of pure interferons and of getting at 
other questions concerning the gene structure and regulation 
of these proteins. Hence the cloning and expression of human 
C/ interferons was undertaken. 
Plasmids containing cDNA copies of interferon-specific 
mRNA were constructed as follows [21] (Fig 2): Leukocytes 
were stimulated by viruses for the production of interferon. 
The mRNA was extracted from these cells and was transcribed 
into DNA copies that were then ligated into bacterial plasmids. 
These were then used to transform E. coli. Individual trans­
formed colonies were screened for the presence of DNA com­
plementary to mRNA from interferon-producing cells, but not 
complementary to mRNA from cells that had not been induced 
for interferon production (Fig 3). Positive colonies were then 
examined for the presence of interferon-specific sequences (Fig 
4). The denatured plasmid DNA was attached covalently to 
DBM paper. RNA from interferon-producing cells was then 
allowed to hybridize to this DNA, and the paper was extensively 
washed to remove mRNA that was not complementary to the 
plasmid DNA. The bound mRNA was finally eluted from the 
TABLE IV. Relative activities of purified natural human" interferon species in several assays 
Purified interferon 
species 
lY, 
0:'2 
#2 
/3, 
"Y1 
"Y2 
Yl 
,. 
"Y5 
-- .... _--. 
Growth inhibitory 
activity (GIA) 
(percent of control) ._-.. . _--
32 
44 
63 
76 
55 
56 
71 
50 
.54 
Antiviral activity 
(unitsfml) uGIA/AV unit" 
5.1 13.3 
7.7 7.3 
0.6 62 
7.3 3.3 
6 7.5 
1.5 29 
3.0 9.7 
16 3.1 
1.0 46 
a Abbreviations: GIA, growth-inhibitory activity; AV, antiviral activity; �GIA = 100 - GIA. Data from [15]. 
bData from [20]. 
Natural killer 
enhancement· 
Low 
Low 
High 
High 
High 
Low 
Low 
Low 
Low 
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FIG 2. Preparation of interferon recombinant DNA plasmids from 
mRNA extracted from induced cells. (Reproduced from [49J with per­
m��sion.) 
CLONE SCREENING: HYBRIDIZATION 
x + y LABELED 
X EXCESS UNLABELED 
mRNAIND* 
mRNAUNIND 
\�------------__ -, ______________ -JI 
1 
COLONY HYBRIDIZATION 
0000 0  
0.00 0 
00000 
FIG 3. Schematic outline of hybridization procedure. [.12PlmRNA 
from induced cells binds preferentially to sequences specific for the 
induced cells when excess unlabeled mRNA from uninduced cells is 
present as a competitor. The induced specific sequences include inter­
feron sequences and other sequences that are induced, including mito­
chondrial ribosomal RNA. (Reproduced from [49J with permission.) 
paper and was injected into frog oocytes. Extracts from the 
frog oocytes were assayed for human interferon activity. The 
presence of such activity demonstrated that the mRNA that 
had been injected was specific for interferon and hence that 
the DNA to which it had hybridized on the filter paper had 
sequences corresponding to the interferon genes. When the 
nucleotide sequence of our first bacterial plasmid (p104) con­
taining the coding region for interferon was compared with the 
available amino acid sequence of purified 0' interferon, it was 
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discovered that only about 80% of the DNA sequence was in 
the plasmid [21]. Shortly before, Nagata et al [22] reported the 
cloning of human leukocyte (0') interferon [23]; even earlier, 
Taniguchi et al [24] reported the cloning of human fibroblast 
({3) interferon. 
This original plasmid (p104), while not itself containing the 
full-length copy of interferon cDNA, was instrumental in find­
ing other plasmids that had full-length copies of the a-inter­
feron mRNA [25]. A number of such plasmids containing cDNA 
from interferon-specific mRNA were identified [26]. From 
these sequences, the amino acid sequences of the proteins were 
predicted (Fig 5). The sequences illustrate that the leukocyte 
interferons are a highly conserved family of proteins. In several 
cases it has been possible to correlate the natural and recom­
binant leukocyte interferons (Table V). 
The original cDNA clones also provided a probe for identi­
fying DNA from the human genome containing sequences 
corresponding to the interferon genes. Thus far at least 12 
distinct genomic sequences from a human embryonic DNA 
library in bacteriophage A have been found in our laboratory 
and others [25,27-30]. The existence of these distinct genomic 
sequences confirmed the deduction that the different leukocyte 
interferons are encoded by a closely related family of genes. 
Analysis of the genomic DNA also demonstrated that the genes 
lack introns found in most eukaryotic genes. 
The bacterial plasmids containing the interferon cDNA were 
also used for the engineering of new plasmids that could direct 
the efficient production of interferon in the bacterial host (Fig 
6). First, the cDNA sequence was excised from the bacterial 
plasmid by restriction endonuclease Pst!. Reflecting the general 
structure of eukaryotic mRNAs, the cDNA not only contained 
the information for the protein itself, but also was flanked on 
the 5' end by a sequence encoding the polypeptide leader 
sequence required for the export of the interferon from euLlr­
yotic cells. The coding sequence was also flanked on the 3' end 
by an untranslated sequence followed by a stretch of polyaden­
ylic acid. The interferon recombinant was reconstructed as 
shown in Fig 6. The result was that the sequence coding for the 
leader polypeptide was removed and an ATG initiator codon 
was added to the 5' end of the gene. 
The gene was ligated into a new bacterial plasmid such that 
it was now flanked on the 5' end by the control region of the 
E. coli tryptophan operon (Fig 7). This control region includes 
the RNA polymerase promoter region and a sequence specifying 
CLONE SCREENING' BINDING ACTIVE mRNA 
mRNA 
� 
1111111 tll ------ �B� PA� PLASMID DNA 
� i- � 
I '\
 
BOUND mRNA UNBOUND mRNA 
� /' 
OOCYTE ASSAY 
FIG 4. Schematic illustration of tbe screening of recombinants with 
DBM paper. Plasmid DNA from one or several colonies is denatured 
and covalently bound to DBM paper. mRNA from cells synthesizing 
interferon is hybridized to the filters, which are then extensively rinsed. 
Strongly bound mRNA is eluted and injected into Xenopus laevis 
oocytes. The production of buman interferon by the oocytes implies 
that the plasmid DNA on the filter contains a sequence homologous to 
interferon mRNA. (Reproduced from [49J with permission.) 
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51 510 520 523 
A a2 
B aB 
C 
Met Ala Leu Thr Phe Ala leu leu Val Ala Leu Leu Val Leu $er Cys Lys Ser Ser Cys Ser Va 1 Gly 
o al 
F 
G a5 
H 
1 
J2 a7 
K a6 
L alO 
.4B 
Tyr 
Ser Ser 
Ser Pro 
Ser Ser 
Pro Val 
Pro Ser 
Ser Ser 
Arg $er Ser 
Pro 
Ser S�r 
Ser Ser 
Met Val Tyr Phe $er leu 
Met Val Tyr lie leu 
Met Va I Val leu 
Met Val Tyr lie leu 
Met Val Asn lie leu 
Met Met Val leu 
Met Val Tyr Ile leu 
Met Va 1 Val Tyr Ile leu 
Met Val leu Asp 
Met Val Tyr lie END leu 
Met Vdl Tyr Ile leu 
10 20 
A 02 Cys Asp leu Pro Gln Thr H1s Ser Leu Gly Ser Arg Arg Thr leu Met Leu leu Ala Gln Met Arg lys Jle Ser 
B a8 Asn Ala Ile Arg 
C Asn Ala I Ie Gly Gly Arg 
o al Glu Asp Asn Ser Arg 
F Asn Ala lie Gly Arg 
G a5 Ser Asn I le Met Gly Arg 
H Asn Ser Asn Asn Met Arg 
I Asn Ala lie Gly Arg 
J2 a7 Arg Asn Ala lie Gly Arg 
K .6 H1s Met Arg 
l.1O Thr Arg Asn Ala Ile Gly Gly Arg 
.4B Asn Ala lie Gly Arg 
m � � 
A .2 
B .B 
C 
o .1 
F 
G .5 
H 
I 
J2 .7 
K .6 
l .10 
.4B 
A .2 
B .8 
C 
o .1 
F 
G .5 
H 
I 
J2 .7 
K .6 
l .10 
.4B 
A .2 
B .8 
C 
o .1 
F 
G .5 
H 
I 
J2 .7 
K .6 
l.lO 
.4B 
A .2 
8 .8 
C 
o .1 
F 
G .5 
H 
I 
J2 .7 
K .6 
l .10 
.4B 
A .2 
B 08 
C 
o .1 
F 
G .5 
H 
I 
J2 .7 
K .6 
l .10 
a4B 
A .2 
B .8 
C 
o .1 
F 
G .5 
H 
1 
J2 .7 
K .6 
l .10 
.4B 
Leu Phe Ser Cys leu Lys Asp Arg H1s Asp Phe G1y Phe Pro Gln Glu Glu Phe --- Gly Asn Gln Phe Gln lys 
Pro Glu Asp Asp Lys 
Pro Arg Ile Asp 
Pro Ser Mrt Asp 
Pro Asp 
Pro Asp 
Pro G1 u Asp 
Pro PrO leu Asp 
Pro Glu Arg Glu Asp H1s 
Arg Asp 
Pro Arg Ile Asp 
H1s Glu Asp H1s 
60 70 
Ala Glu Thr J1e Pro V� 1 Leu His Gll) Met J le Gln Gln Ile Phe Asn leu Phe Ser Thr Lys Asp Ser Ser Ala 
Gln Ala Ser Thr 
Gln Ala Ser Thr Glu 
Pro Ala Ser Le-u Thr 
Gin Ala Ser Thr 
Gln Ala Ser Thr 
Gln A'a Ser Met Thr Asn 
Thr Gln Ala Ser Thr Glu 
Thr Gln Ala Ser Thr G 1u 
Ala Ser Val Thr Val 
Gln Ala Ser Thr Glu 
Thr Gln Ala Ser Thr Glu 
80 9C 100 
Ala Trp Asp Glu Thr Leu Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu Glu Ala Cys Val 
Leu Glu lle Asp Val Leu Cys 
Glu Gin Ser Glu Ser 
Asp Cys 
Thr Glu Gln Ser Glu Ser Asn Met 
Thr Met 
Glu Ile Phe Met 
Glu Gln Ser Glu Ser As" 
Glu Gln Ser Glu Ser 
Arg leu 
Glu Gln Ser Glu Ser I Ie 
Glu Gln Ser Glu Ser 
110 120 
Ile Gin Gly Val Gly Val Thr Glu Thr Pro Leu Met Lys Glu Asp Ser Ile leu Ala Val Arg lys Tyr Phe Gln 
Asp Glu 
Glu 
Met Glu Glu Arg 
Glu 
Met 
Met 
Glu 
Glu 
Glu 
Glu 
Glu 
Glu 
Glu 
Trp 
130 
lle Ser Tyr 
Glu Asn 
Gly Asn Val 
Glu Asn Val 
Glu Asp Asn Val 
Glu A,n 
Met Glu Asn 
Glu Asn 
Gly Gly Asn 
G1 u Asn 
Glu Asn '1al 
Thr 
Phe 
lys 
lys 
Lys 
Arg 
lW 1� 
Arg Ile Thr Leu Tyr Leu Lys Glu Lys 
Thr 
lys Tyr Ser Pro Cys Ala Trp Glu Val Val Arg Ala Glu ll� Met Arg 
Ser 
lle Arg 
Thr 
Thr 
Thr 
Met 
Thr 
Met 
Thr 
Ile Arg 
Thr 
160 166 
Ser Phe Ser Leu Ser lt1r Asn Leu Gln Glu Ser leu Arg $er lys G�u 
Ile lys Arg lys 
Leu Phe lys Arg Arg Asp 
leu Arg Arg 
lys I Ie Phe Arg Arg 
Ala Arg Arg 
Phe Lys Arg Arg Asp 
leu Phe lys Il e Arg Asp 
Ph. lys Arg Arg Asp 
Ser Arg Arg Arg 
leu Phe lys Arg Arg Asp 
leu Phe Lys Arg Arg Asp 
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FIG 5. Summary of amino acid se· 
quences of human leukocyte interferons. 
Sequences were derived from the respec· 
tive DNA sequences. The entire se· 
quence of IFN -aA is given, including the 
sequence of the precursor signal peptide 
(SI-S23). Corresponding residues of the 
other species are shown only where they 
differ from those of IFN-aA. Since IFN­
aA has only 165 amino acids, whereas 
the other species have 166 amino acids, 
a gap in the IFN -aA sequence has been 
introduced between residues 43 and 44 
to provide maximum homology with the 
other species. Sequences A through L are 
from the laboratory of the authors and 
from that of Goeddel and coworkers 
[26,49-51]. Sequences prefixed by a are 
from the laboratory of Weissmann et al 
[29]. Sequences that differ by only a few 
amino acids are here listed together (e.g., 
there is a single amino acid difference 
between A and ,,2). The a5 sequence is 
complete, whereas the G sequence begins 
at residue 34, since only a partial-length 
clone of this recombinant was isolated; 
identity of G with a5 is proposed on the 
basis of the extant sequences. a4B was 
described by Weissmann et al [29]. 
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TARLE V. Correlation of natural and recombinant human leukocyte 
interferons 
Natural 
Recombinant a 
Leukocytes b Myeloblasts' 
"Corresponding species are connected by lines; from [25,26,:ilJ and 
unpublished data. 
"From [llJ. 
'From [19]; the a species from myeloblasts have not been purified 
to homogeneity. 
CONSTRUCTION OF EXPRESSION PLASM I D 
SOu50 
PSi} Avo] BqiTI 
50Ll30 So�' 30 
AVOII: Psl1 
�""�'�50�b·P"""""�6�70�b·P""""""" 
34 bp � 
lsou3a, Ayah 
(34 bp) 
AATTC:"T::;T::;T ::;ATCTG AGGAG 
G:-ACACACTiI.G AC--TCCTCCH; 
�GASC 
3 
TG 
AATTC 
G 
EceRI 45bp Avo II 
, 2 
4vo:::I 
Bq/ II 
Agill 
670 bp 
fuRl Met ;�� ��� �von BgiJ. Pst I 
ACA crA ....... -......................... ..;.c 86�) Dp 
ps!I 
FIG 6. Construction of expression plasmid for human leukocyte 
interferon. A eDNA recombinant plasmid for leukocyte A interferon 
was isolated. The PstI insert containing the complete eDNA sequence 
was excised. The three fragments shown above were isolated. The 
Sau:la-Auall fragments corresponds to amino acids 2 to l:i of the 
mature interferon. A synthetic DNA was synthesized that restored the 
TGT codon of Cysl, introduced a methionine initiation codon (ATG) 
to the 5' side of the Cysl codon, and contained EcoRl and 8au:ia 
restriction sites. This was ligated to the 8au:3a-Avall fragment; the 
resultant fragme nt was ligated to the 150-bp AvaII-BglIl and 670-bp 
HglII-PstI fragments . This final expression fragment contained the 
coding sequence for a mature leukocyte interferon with an additional 
methionine at the NH,-terminal end. This was ligated to the r;. coli 
tryptophan promoter-operator for high-efficiency expression in E. coli. 
(Reproduced by permission from [49J; data from (aI].) 
the ribosome binding site. When this "expression vector" was 
introduced into E. coli and the bacteria were cultured on a large 
scale, the culture produced high yields of a single species of 
interferon, greater than 2 x 10" units of interferon per liter of 
culture (about 1 mg). Currently it is possible to produce about 
1 x 10JII units (50 mg) per liter with improved expression 
vectors. For comparison, the purification of interferon from 
cultured human KG-l cells yielded a mixture of IFN -it species 
totaling about :3 x 10' units per liter (approximately 100 pg). 
The first crystals of human leukocyte interferon were pre­
pared by Drs. Miller, Kung, and Pestka [32] as a step toward 
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the analysis of its three-dimensional structure by x-ray crys­
tallography. In addition, purified interferon was now available 
in large quantities for in vitro functional studies, for animal 
studies, and for human clinical trials. 
MONOCLONAL ANTIBODIES TO INTERFERON 
In experiments that were progressing simultaneously with 
the purification of the natural interferons, an array of mono­
clonal antibodies was produced in collaboration with Theophil 
Staehelin and his colleagues in Basel [3:3]. These monoclonal 
antibodies permitted the development of convenient solid­
phase radioimmunoassays for interferon [:34], as well as the 
development of immunoaffinity columns for the rapid purifi­
cation of interferon from both natural and bacterial sources 
[35]. Additional possibilities for their use have arisen from the 
demonstration that many of these antibodies preferentially 
recognize native interferon rather than heat-denatured or 
chemically inactivated interferon [:36]. 
INTERFERONS WITH NOVEL PROPERTIES 
Plasmids containing interferon-specific DNA sequences have 
been utilized to create novel synthetic DNA genes by splicing 
parts of the natural genes together [37-39] (Fig 8). Because of 
the existence of common restriction endonuclease sites in the 
REGULATION OF INTERFERON EXPRESSION 
TRYPTOPHAN 
PROMOTER 
I 
INTERFERON 
CODING REGION 
1 
INTERFERON 
I 
FIG 7. Schematic illustration of the DNA construction for the 
expression of mature interferon in E. coli. Here it is under the control 
of the tryptophan operator-promoter and has a proper g coli ribosome 
binding site. (Reprinted by permission from /49}.) 
END OF CODING REGION 
BASE 0 200 400 
i 
600 800 
PAIRS I I I I I 
Bgill Pvull Bgill 
A I I 
DdeI Bgill Pvull EcoRI 
D II I 
BgllI PvulI EcoRI 
AD (PvulI) I I 
Bgill Pvull EcoRI 
AD (BgllI) I I 
DdeI Bgill Pvull 8gll1 
DA(PvulI) ,I I I 
DdeI Bgill Pvull Bgill 
DA(8gllI) II I I 
Bgm Pvull Bgill 
ADA (Bgl][- PvulI) I I 
FIG 8. Schematic illustration and restriction maps of the coding 
regions for the mature protei ns of the plasmids pIFN-aA and pIFN­
"D and the hybrids constructed from these sequences. (Reprinted by 
permission from (49}.) 
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closely related interferon genes, it was possible to cut the 
recombinant cDNA molecules at the common sites and to 
religate the pieces in new combinations to form novel mole­
cules. Several such hybrids were formed from the two interferon 
clones designated A and D, which were cut by the restriction 
endonucleases B/?lII and Pvull. These new sequences were 
engineered for efficient expression in E. coli, and the resulting 
proteins were tested functionally. 
The potency of the parental and hybrid interferons in the 
viral cytopathic effect inhibition assay on cells from several 
species is shown in Table VI. These data rep:es�n� the num�er 
of molecules of interferon per cell for 50% mhlbltlon of viral 
cytopathic effect. The parental A and D molecules are both 
q� ite active on bovine MDBK cells, but they exhibit different 
activities on human cells and are relatively inactive on mouse 
L cells. This lack of activity on mouse cells is a general property 
of human interferons. The hybrid proteins that were spliced at 
the B/?III or Pvull restriction sites, having the NH2 terminus 
of the A molecule and the COOH terminus of the D molecule, 
had a specificity similar to the parental A molecule on human 
or bovine cells. Completely unexpectedly, however, these pro­
teins were quite active on mouse L cells, in contrast to all 
known human interferons. The converse construction, where 
the NH2 terminus of D was ligated to the COOH terminus ?f 
A, produced proteins that resembled the parental molecules m 
being relatively ineffective on mouse cells. 
These experiments demonstrated that the species specificity 
of the parental A and D interferons segregated with portions 
of the molecule. Similarly, when the parental and hybrid pro­
teins were tested for antiproliferative activity on human Daudi 
cells, their potency ranged over a factor of 5000-fold (Table 
VII). The ratios of antiproliferative to antiviral activity were 
seen to vary considerably (Table VII). As discussed earlier, this 
ability of different leukocyte interferons to activate different 
cellular responses to various extents suggests that the biochem­
ical pathways of these responses diverge at some point, possibly 
as earlv as the interferon-receptor interaction. Finally, the 
finding
' 
that the A/D hybrids were active on mouse cells dem­
onstrated the potential of creating more diversity and possibly 
novel activities in the leukocyte interferons by manipulating 
the sequences by recombinant DNA technology. 
TABLE VI. Molecules per cell for 50% inhibition of viral cytopathic 
effect for various cell lines" 
Interferon/ A(;-1732 MDBK L cells 
cell type (human) (bovine) (murine) 
A 4,900 1,100 3.1 X 107 
D 360,000 6,600 4.3 X 106 
A/D (Bgll 5,500 1,200 3,300 
A/D (I'l'u) 4,100 2,400 48,000 
D/A (Bgl) 1.:; X 106 1,800 >7.2 X 107 
D/A (Puu) 590,000 5,400 7.1 X 106 
A/D/A 36,000 2,000 1.1 X 106 -
"Data from [:\9]. 
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PURIFICATION AND CLONING OF HUMAN 
FIBROBLAST ({3) INTERFERON 
Human {3 (fibroblast) interferon and its gene have also been 
investigated. Several laboratories had reported the purification 
of human {3 interferon by SDS-polyacrylamide gel electropho­
resis as the last step of purification [40,41]. We developed a 
simple purification procedure involving Blue-Sepharose chro­
matography followed by HPLC on octyl silica [42]. This pro­
cedure produced pure {3 interferon free of salts, solvents, and 
SDS. The specific activity of this material was 3 X 108 units 
per milligram of protein. The amino acid compositi?n and t�e 
sequence of the first 19 amino acids were determmed. ThiS 
sequence confirmed and extended those reported earlier for the 
first 13 [43,44], and 10 residues [45]. Subsequently, this se­
quence was shown to be identical to that predicted from the 
nucleotide sequence of the cloned DNA. 
The cloning and expression of the (3 interferon gene was 
accomplished in collaboration with Goeddel and coworkers [46) 
by procedures similar to those described for the cloning and 
expression of the a interferons. A cDNA library was can· 
structed with mRNA from human fibroblasts induced with 
polyinosinic· polycytidyic acid. A bacterial clone containing the 
fibroblast cDNA was identified by hybridization to radio I abe led 
cDNA prepared from 128 mRNA from induced fibroblasts as 
template for the reverse transcriptase and synthetic oligonu· 
cleotides predicted from the NH2-terminal amino acids as 
primers. The nucleotide sequence of a plasmid from the eDNA 
library was determined, allowing deduction of the total amino 
acid sequence of the fibroblast interferon and of its export 
signal sequence. An expression plasmid was t,!ten
. 
constructed 
that permitted the synthesis in E. coli of 8 X 10' UllltS of human 
{3 interferon per liter of culture. The interferon thus produced 
was indistinguishable from natural human {3 interferon by 
several criteria, although it lacks the carbohydrate moieties 
found on the natural {3 interferon. Since the amino acid se· 
quences of {3 interferon and the nucleotide sequences of the 
eDNA cloned in several laboratories are in agreement 
[23,24,46-48], it seems that there is only a single major species 
of {3 interferon encoded by a single gene. Some evidence for 
molecular heterogeneity has been reported but not fully sub· 
stantiated [5]. 
SUMMARY AND CONCLUSION 
The human a (leukocyte) interferons are a family of closely 
related molecules, many of which can be simultaneously in­
duced. At least nine of these natural a interferons have been 
purified from several human sources. They have been chara<;­
terized in terms of their species specificity in antiviral assays. 
In addition, their antiviral, antiproliferative, and natural killer 
cell stimulatory activities on human cells have been compared. 
The variations in the absolute activities of the a interferons 
demonstrate that the chemical diversity is mirrored in func­
tional diversity. 
A number of human IFN -a species have been cloned. These 
TABLE VII. Molecules per cell for 50% inhibition of uariol/.5 assays on human cells 
Interferon Antiviralo 
A 4,900 
D 360,000 
A/D (Hgl) 5,500 
A/D (Puu) 4,100 
D/ A (EMil l.5 X 10" 
D/A (1'[,11) 590,0()() 
A/D/A 36,000 
"Measured on AG-1732 cells [��9]. 
h Measured on Daudi lymphoblastoid cells [39]. 
, Measured on natural killer cells [52, 53]. 
Antiproliferativeb 
1 3 ,000 
450,000 
9,300 
30,000 
910,000 
4.2 X 10" 
60,000 
Natural killer cell 
enhancementC - --
118 
2.8 X 105 
58 
1,300 
2.5 X 105 
46,000 
20,000 
AV/AP AV/NK 
0.38 41 
1.80 1.3 
0.59 95 
0. 14 3.2 
1.7 6.0 
0.14 13 
0.60 1 .8 
July 1 984 
have been efficiently expressed in E. coli to produce purified 
interferon proteins. The large -scale production of genetically 
engineered interferon has made possible further physical and 
chemical characterization of the proteins, including the crys ­
tallization of human leukocyte interferon A. This material has 
also been used for extensive animal and human clinical trials. 
The genes for the natural leukocyte interferon species have 
been genetically engineered to form hybrid genes coding for 
corresponding chimeric proteins. The hybrid proteins had some 
novel and unexpected characteristics,  such as activity on mouse 
cells , which are generally insensitive to protection by human 
interferons. 
The observation that the relative potencies of the leukocyte 
species, whether natural, recombinant, or hybrid, do not nec ­
essarily correlate among the various functional assays suggests 
that the biological effects are differentially activated and hence 
must proceed along different biochemical pathways . The 
branchpoint for this differential activation of pathways is not 
known, but it could be as early as the recognition step by the 
cellular receptor, which itself could conceivably be a family of 
molecules.  
The fact that the leukocyte interferon species are function­
ally distinct, despite their high degree of relatedness, as well as 
the fact that the genetic recombination of parts of the molecules 
may lead to new and unexpected functional changes, has several 
implications for the investigation of the therapeutic properties 
of interferon . First, for any application, each species will have 
to be tested for efficacy. Second, the usefulness of genetic 
engineering technology in this area not only m ight be in the 
production of large amounts of interferon, but also might be in 
the production of novel modified interferons that have such 
desirable combinations of properties as high specific potency 
for a particular application and low overall toxicity. The finding 
of differential activation of biological effects makes this decou­
piing of desirable and undesirable properties theoretically rea­
sonable. However, any rational approach to the therapeutics of 
such a varied family of molecules will depend on continuing 
experiments designed to identify the structural basis of the 
differential biological responses as well as experiments on the 
nature of the cellular receptor and the subsequent biochemical 
mechanisms involved. 
We are pleased to thank Sophie Cuber and Pamela Van Wyck for 
their assistance in preparing this manuscript. 
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